As most of us know...there's plenty to look forward to as 2013 ought to be just about as big as it can get for the T and OM compounds. Money situation looks quite good and the deal with AMGEN seems to be quite solid....nice to know that a substantial sum of the 600 Mill is npt subject to OM first going to market and thus shortening the time for CYTK to get some strong money flowing in....so now we wait.
Hawk, I also listened and your recap was excellent. Blum did say that they expect the Amgen-partnered trial to proceed from cohort 2 to cohort 3. I'm surprised CYTK hasn't moved up today, but it does give retail buyers a fast closing window to buy cheap.